Practice Point | Published:

Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Cunningham D et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345

  2. 2

    Saltz LB et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201–1208

  3. 3

    Lenz HJ et al. (2004) Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. ASCO Meeting Abstracts 22: 3510

  4. 4

    Scartozzi M et al. (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22: 4720–4726

Download references


The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Correspondence to José Baselga.

Ethics declarations

Competing interests

J Baselga has received honoraria from Merck KGaA.



Memorial Sloan-Kettering Cancer Center


Reverse transcriptase polymerase chain reaction; a variation of the PCR technique in which cDNA is made from RNA via reverse transcription and the cDNA is then amplified using standard PCR protocols

Rights and permissions

Reprints and Permissions

About this article

Further reading